Solara Active Pharma Sciences Q4: Revenue Dips, Narrow Net Loss, Margin Expansion in Focus

Unknown Apr 02, 2026 1,100 Views

Solara Active Pharma Sciences Ltd reported its financial results for the quarter ended March 2025, reflecting a challenging but improving operational landscape. The company posted consolidated revenue from operations of ₹2.73 billion, marking an 8.8% decline year-on-year as competitive pressures...

Key Highlights:

Revenue Performance: Q4 consolidated revenue stood at ₹2.73 billion, down from ₹2.99 billion in the same quarter last year, primarily due to intensified competition in the Ibuprofen segment and a strategic shift toward higher-margin products.
Net Loss Narrows Sharply: The company reported a consolidated net loss of ₹21 million for the quarter, a significant improvement from the previous year’s net loss of ₹2.55 billion. This turnaround reflects effective cost control and a focus on profitability.
EBITDA Surge: EBITDA for the quarter soared to ₹513 million, up 347.8% year-on-year, with margins expanding due to operational efficiencies and a better product mix.
Margin Expansion Strategy: Solara continues to prioritize margin expansion, with Q4 gross margins returning to historical levels and EBITDA margins trending toward the company’s guided exit rate of 20-22%.
Operational Excellence: The Ambernath manufacturing facility cleared a recent USFDA inspection with zero observations, reinforcing Solara’s commitment to quality and regulatory compliance.
Revised Guidance: Management has revised full-year revenue guidance downward, citing ongoing price pressure in legacy products, but remains confident in sustaining improved margins and operational discipline.
Market Response: Shares of Solara Active Pharma Sciences closed at ₹575.60 on May 13, 2025, reflecting cautious optimism from investors as the company navigates its turnaround.